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Photosensitizers: From drug design to animal testing 
 
 
The therapeutic properties of light have been known for thousands of 
years, but it was only in the last century that photodynamic therapy 
(PDT) was developed. As an emerging therapy for the treatment of a 
variety of diseases, there has been extensive research into the design of 
new photosensitizers and drug delivery systems. A general introduction 
to the drug discovery of a new photosensitizer and the aim of this thesis 
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1.1. PHOTODYNAMIC THERAPY OF CANCER: general aspects 
Photodynamic therapy (PDT) involves the administration of a photoactive dye or 
photosensitizer (PS) that is able to produce reactive oxygen species (ROS) upon 
irradiation with light. When the PS absorbs a photon, an electron is promoted from the 
ground state to an electronically-excited state that can then undergo electron transfer 
(type I reaction) generating superoxide, hydrogen peroxide and hydroxyl radicals; or 
can transfer energy to molecular oxygen to produce highly cytotoxic singlet oxygen 
(type II reaction) (Fig. 1.1) [1]. Both mechanisms can produce the photo-oxidation of 
certain amino acids, pyrimidine and purine bases of DNA/RNA, and unsaturated lipids, 
leading to DNA damage and/or damage to the cytoplasmic membrane allowing 




Figure 1.1. Jablosnki diagram depicting the possible photophysical properties and the mechanisms of 
ROS generation.   
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There are multiple applications of this therapy, including antimicrobial therapy, age-
related macular degeneration (AMD), acne and dermatological diseases, and cancer.  
Photodynamic therapy of cancer is particularly attractive because of its fundamental 
specificity and selectivity. As described above, PDT involves the combination of three 
individually non-toxic components (PS, visible light and molecular oxygen) to induce 
cellular and tissue effects. Thus, this treatment shows a dual selectivity that is 
produced by both a preferential uptake of the PS by the diseased tissue and the ability 
to confine activation of PS by restricting the illumination to that specific area.  
Although it was initially considered that PDT-induced damage was confined to the 
treated site, it is now accepted that this therapy is endowed with multifactorial effects, 
which include direct tumor cell killing, damage to the tumor vasculature and activation 
of the immune system [1]. It is generally accepted that all three mechanisms are 
necessary for the optimal tumor damage. The relative contribution of these pathways 
depends upon the PS used, the tissue being treated, and the treatment conditions. 
ROS generated by PDT can kill cells directly by apoptosis, necrosis and/or autophagy 
if the PS has been taken up by tumor cells. However, complete tumor eradication is not 
always fully realized by this mechanism mainly due to the non-homogeneous 
distribution of the PS and oxygen concentration within the tumor [1,3]. 
PDT also damages the tumor-associated vasculature. An initial blanching and 
vasoconstriction of the tumor vessels is followed by acute blood stasis, hemorrhage 
and the formation of platelet aggregates, that provokes the vascular shut-down.  As a 
result, tumor cells become deprived from oxygen and nutrient supply, leading to the 
elimination of the tumor  [4,5].  
PDT triggers several cell-signaling cascades and the release of cell fragments, 
cytokines and inflammatory mediators that stimulate a complex interplay between the 
innate and the adaptive arms of the immune system to recognize and destroy tumor 
cells even at isolated locations  [6-8]. 
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1.2. DRUG DISCOVERY 
In the fields of medicine, biotechnology and pharmacology, drug discovery is the 
process by which drugs are discovered or designed. The process of drug discovery for 
PDT involves the identification and synthesis of the PS, its photophysical 
characterization, the development of a formulation and assays for therapeutic PDT 
efficacy both in vitro and in vivo. Once a compound has shown its value in these tests, 
it will begin the process of drug development prior to clinical trials.  
 
1.2.1. Photosensitizers 
Photosensitizers (PSs) are exogenous or endogenous chemicals that cause 
sensitization to light. Exogenous PSs tend to be relatively large molecules and are 
usually administered parentally, while the endogenous PS protoporphyrin IX (PpIX) can 
be induced by topical delivery of 5-aminolevulinic acid (ALA)  [9]. 
An ideal PS agent should be single pure compound with easy and low cost synthesis, 
and should have chemical and physical stability. It should have a high absorption peak 
between 600 and 800 nm, the so-called therapeutic window, which allows the 
maximum light penetration through the tissue with the minimum light scattering. It 
should have high singlet oxygen quantum yield for high photodynamic efficiency but 
also be fluorescent and photostable to facilitate monitoring. It should be devoid of any 
toxicity without light, and also show selective uptake, rapid clearance from normal 
tissues to minimize skin photosensitivity and other side effects, and microlocalization to 
sensitive cellular/subcellular targets (e.g. mitochondria)  [10,11].  
Since the development of porfimer sodium (Photofrin®) in the last part of the 20th 
Century, there has been a concerted effort to develop new, more potent, tumor-specific 
agents with the overall aim of improving therapeutic outcomes for patients. Although 
Photofrin® is still the most widely used PS, the product has some disadvantages, 
including long-lasting skin photosensitivity and relatively low absorbance at 630 nm. 
After Photofrin® several hundred compounds, referred to as second-generation PSs, 
have been proposed as potentially useful for anticancer PDT. The main classes are 
synthetic porphyrin, porphycenes, chlorins, bacteriochlorins and phthalocyanines. Their 
core structures are depicted in Fig. 1.2. Table 1.1 displays the most promising PSs that 
have been used clinically for cancer PDT (whether approved or in trials). 




Figure 1.2. Core structures of the main kinds of second-generation PSs. 
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Our group has focused the interest in the porphycene family. Porphycenes are 
structural isomers of porphyrins that have many unique properties and features  [12]. 
The most relevant feature of the porphycene ring is its lower structural symmetry that 
results in 20-fold larger absorption coefficients in the red part of the spectrum 
compared to porphyrins. Since the synthesis of the first porphycene in 1986  [13], a 
variety of substituted derivatives have been prepared  [14].  The  excellent  porphycene’s  
photophysical properties, as well as its ability to photoinactivate several cell lines  [15-
18], promote the porphycenes as promising PSs for PDT treatments. 
 
1.2.2. Drug delivery systems 
Most PS molecules tend to be highly hydrophobic and therefore aggregate easily in 
aqueous environment  [19]. The presence of hydrophobic interactions lowers the 
efficiency of the PS, which must be in monomeric form to be photoactive. Moreover, 
selective accumulation of the PS in diseases tissues is required to minimize unwanted 
side-effects result from damage to healthy cells. Thus, considerable efforts have been 
directed at designing delivery systems that can incorporate PS in monomeric form 
without diminishing its activity, and without causing any harmful effects in vivo  [20]. 
Different strategies have been investigated. Fig. 1.3 shows a selected representation of 
the drug delivery systems most used for PDT.  
 
 
Figure 1.3. Drug delivery systems most used in PDT. 
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Polymeric nanoparticles (NPs) have recently emerged as a promising tool for the 
delivery of drugs in PDT, mainly because their flexibility toward surface modification 
and the possibility of being loaded with multiple components such as targeting ligands 
and contrast agents. A variety of polymeric NPs has been developed including 
synthetic polymers like polylactide-polyglycolide copolymers (PLGA), N-(2-
hydroxypropyel)methacrylamide (HPMA), and polyacrylamide (PAA). Natural polymers 
composed of polysaccharides, such as chitosan and alginate, and proteins such as 
albumin, and collagen, have also been used  [21-24].  
Otherwise, silica NPs have several advantages as carriers for PDT agents: their 
particle size, shape, porosity and mono-dispersibility can be easily controlled during 
their preparation. They are pH stable and are not subject to microbial attack. 
Furthermore, a variety of precursors and methods are available for their synthesis 
allowing numerous PDT drugs to be encapsulated. Although these NPs do not release 
the entrapped PS, the porosity of the silica wall permeates the produced singlet oxygen 
and the desired phototoxic effect is maintained even in the encapsulated form  [23,25]. 
Gold NPs have been used in two ways in PDT: firstly as drug-delivery platforms in a 
similar manner to other inorganic NPs  [26]; secondly as surface plasmon-enhanced 
agents taking account of the non-linear-optical fields associated with very close 
distances to metal NPs  [27,28]. 
Lipoproteins are naturally occurring NPs composed of a mixture of specific proteins, 
phospholipids and cholesterol with a hydrophobic core. The family consists of 
chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins (LDL) and 
high density lipoproteins (HDL). Their small size (less than 30 nm) allows them to 
penetrate deeply into tumors. Furthermore, LDL has innate cancer targeting potential 
as LDL receptors are overexpressed on malignant cells  [29].   
Alternatively, micelles are suitable for the formulation of PSs. Their hydrophobic core 
can accommodate hydrophobic drugs, whereas their hydrophilic shell, which is usually 
composed of PEG, in combination with their small size (10-100 nm) results in long 
circulation times and selective accumulation at the tumor site. Several components 
have been studied for loading PS. Pluronic micelles, polymeric micelles using 
poly(ethylene glycol)-b-poly(caprolactone) (PEG-PCL) or poly(ethylene glycol)-b-
poly(DL-lactic acid) (PEG-PLA) diblock copolymers, lipid-based PEG-PE or Cremophor 
EL have been extensively used for loading PSs for PDT  [30,31]. 
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Liposomes have far been the most intensively studied carrier system for PS, 
therapeutic drugs and cosmetic delivery due to their unique properties [32-36]. 
Conventional liposomes are highly biocompatible and biodegradable nanocarriers 
composed of a unilamellar or multilamellar phospholipid bilayer surrounding an 
aqueous inner core. In fact, they can contain a wide variety of hydrophilic and 
hydrophobic diagnostic or therapeutic agents, providing a larger drug payload per 
particle and protecting encapsulated agents from metabolic processes  [37].  
Among all the options, our group has opted for liposomes for the delivery of 
photosensitizing agents  [38-40]. Once the PS has been incorporated in the liposomes, 
it can be delivered to cells in two interlocking ways, modulated by the nature of lipids 
and type of cell: cationic liposomes tend to fuse with cell membranes or endosomes 
and release its contents into the cytosol, whereas neutral or negatively-charged 
liposomes can be taken up by endocytosis and then disintegrated in endosomes or 
lysosomes, again releasing the active drug into the cell  [41,42].  
Due to the fast angiogenesis in malignant tissue, tumor vessel walls show an 
enhanced vascular permeability allowing liposomes to passively accumulate in tumor 
tissue at high concentrations  [33]. However,  such   “conventional”   liposomes  have   the  
drawback of a short plasma half-life in vivo, of the order of minutes. This is firstly due to 
rapid lipid exchange between the liposomes and lipoproteins and the easy 
opsonization by plasma proteins. To improve the pharmacokinetics and antitumor 
therapeutic efficacy, sterically stabilized liposomes were developed  [43]. The surface 
of the liposome is decorated with hydrophilic carbohydrates or polymers, such as 
monosialoganglioside or polyethylene glycol, in order to extend the in vivo liposome 
circulating time.  
Various strategies have been investigated to trigger the release of the encapsulated 
drug from liposomes at the optimal location and time, such as pH-triggered and redox-
triggered release  [44]. Some methods have been applied for he release of PS 
specifically at tumor tissue by stimuli such as light, heat or ultrasound  [45]. 
 
Targeted drug delivery systems 
Ideally, PDT holds the promise of dual selectivity due to a preferential tumor uptake of 
the PS and the restricted illuminated area for an improved selectivity. However, 
confined irradiation is not possible, leading to some phototoxicity to surrounding normal 
tissues. Moreover, several cases of prolonged skin photosensitivity have been reported  
Chapter 1: Introduction 
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[46]. Targeted drug delivery systems are one of the strategies proposed to solve these 
problems underlying non-specific PS accumulation. Active targeting encompasses the 
strategy of coupling a specific entity to the surface of the NP, enhancing their selective 
interaction with target cells recognized by specific markers. While monoclonal 
antibodies have received the most attention  [47,48], biochemical, metabolic and 
physiological alterations of tumor cells offer numerous other potent targets to exploit 
during the delivery of PS. Folic acid (vitamin B9) is essential for the proliferation and 
maintenance of cells. The overexpression of folate receptor on a variety of epithelial 
cancer cells and the high affinity of folate for its receptor has attracted wide attention as 
a targeting agent for tumor selectivity  [49,50]. Small peptides that selectively recognize 
tumor cells represent another excellent approach for targeting therapies  [51], and 
hyaluronic acid recognizes CD44, known as the hyaluronic acid receptor, which is 
involved in cell adhesion and is also overexpressed on many cancer cells  [52,53].  
 
1.2.3. In vitro tests 
PDT efficiency is generally tested in vitro as a first approximation to the photodynamic 
action of a PS. Although PDT can induce many cellular and molecular signaling 
pathways events in cells, its main purpose is to induce cell death. The concentration, 
physicochemical properties and subcellular localization of the PS, the concentration of 
oxygen, the appropriate wavelength and intensity of light, as well as the cell type 
specific properties may all influence the mode and the extent of cell death  [54]. 
 
Modes of cell death 
Cells can undergo three different types of cell death after PDT. Necrosis, referred to as 
accidental cell death, is considered to be an unprogrammed process. It is a violent and 
quick form of degeneration characterized by in vitro cytoplasm swelling, devastation of 
organelles and disruption of the plasma membrane, leading to the release of 
intracellular contents and in vivo inflammation  [55]. 
A different type of cell death termed apoptosis represents regulated cell suicide. 
Apoptosis requires transcriptional activation of specific genes, including the activation 
of endonucleases, consequent DNA degradation, and activation of caspases. The 
organelles and plasma membrane tend to retain their structure for quite a long period. 
In vitro, apoptotic cells are usually fragmented into multiple membrane enclosed 
Photosensitizers: From drug design to animal testing 
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spherical vesicles. In vivo, these apoptotic bodies are scavenged by phagocytes, 
inflammation is prevented, and cells die in an immunologically controlled way  [56,57]. 
In spite of this fact, researchers have recently discovered a new apoptotic cell death 
modality called –“immunogenic   apoptosis”,   which   is   provoked   by   the   endoplasmic  
reticulum (ER) stress accompanied by ROS and is able to trigger an effective dendritic 
cell-based antitumor immune response  [58]. 
Autophagy is a process whereby a portion of the cytosol, usually containing cellular 
organelles, is sequestered by a double membrane. The resulted vesicle then fuses with 
a lysosome, the contents are digested, and can be recycle during periods of starvation. 
There is also evidence that autophagy can be a cell-death mode under appropriate 
circumstances, accompanying apoptosis after ER photodamage  [59].  
 
3D cell cultures 
Tissues and organs are three-dimensional (3D). However, the ability to understand 
their formation, function and pathology has often depended on two-dimensional (2D) 
cell culture studies. Standard cell cultures can differ considerable in their morphology, 
cell-cell and cell-matrix interactions, and differentiation from those growing in more 
physiological 3D environments. In vitro 3D tissue models provide an approach that 
bridges the gap between traditional cell culture and animal models  [60]. 3D-cell 
scaffolds have been developed within the tissue engineering field for tissue 
regeneration and organ replacement  [61,62]. However, researchers in the 
photodynamic field have also followed this strategy in order to better mimic the cancer 
tissue environment and optimize the parameters for an efficient PDT outcome in vivo. 
Spheroids have so far been the most intensively studied 3D system for PDT and a 
wide variety of therapy studying the effects on fundamental mechanisms, including 
regulation of proliferation, cell death, differentiation and metabolism. Multicellular 
spheroids are formed by culturing cells in spinner flasks or agar-coated culture plates. 
Under these conditions, cells form spherical clusters that can survive for weeks and 
can reach sizes of up to several millimeters in diameter. Multicellular spheroids offer a 
simple and highly reproducible model that contains many of the features of natural 
tissue  [63]. It has been found that oxygen gradients characteristics of spheroids 
produce heterogeneous response to PDT  [64]. They are also well suited for 
investigating the utility of therapies on tumor cell invasion  [65]. The study of PDT-
induced vascular damage has been recently investigated using a sophisticated 
spheroid-chick chorioallantoic membrane (CAM) system  [66].  
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A basement membrane cell culture approach has been used for the in vitro model of an 
ovarian metastatic cancer  [67]. This strategy uses a synthetic media that contains 
collagen and growth factors that mimic the extracellular matrix (ECM).  
In a similar approach, a novel hydrogel-based 3D culture model has been developed 
for better predict the PDT outcome (see chapter 7). The model uses a self-assembling 
RAD16-I scaffold that forms a network of interweaving nanofibers of 10-20 nm 
diameter and 50-200 nm pore size, surrounding cells in a similar manner to the natural 
extracellular matrix and, thereby, mimicking the in vivo cellular environment.  
Ex-vivo skin models have been used for addressing the photodynamic potential of 
some PS for skin cancer and other malignancies  [68,69].  
 
1.2.4. In vivo tests 
The final step of the PS efficacy evaluation before jump to clinical trials is the in vivo 
(animal) testing. The animals most used for PDT purposes are small rodents such as 
mice and rats, although rabbits, pigs, dogs and cats have also been used. The 
standard protocol involves the subcutaneous inoculation of cancer cells into the 
desired zone, a waiting time until the development of the tumor and the evaluation of 
tumor growth, survival and other effects (e.g. immune response activation) after PDT 
treatment. Even zebra fish have been used as model for studying synergistic effects 
between PDT and a novel ultrasound activated therapy  [70]. The chick chorioallantoic 
membrane (CAM) model is useful for the assessment of PDT-induced vascular 
damage  [71,72]. This in vivo model has the advantage of providing an easily 
accessible neovascular net in a transparent matrix, and therefore vascular effects and 
drug pharmacokinetics are easily measured. 
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1.3. OBJECTIVES 
The main goal of this thesis is to study the efficacy of new porphycene photosensitizers 
and the influence of drug delivery systems in photodynamic therapy. This is divided 
into the following specific objectives: 
 Characterization of the photophysical properties of new porphycene-based 
photosensitizers. 
 Development of liposomal formulations for the encapsulation of photosensitizing 
agents and investigation of the potential of targeting strategy. 
 Assessment of the antitumor potential of a new porphycene photosensitizer in 
vitro and in vivo. 
 Assessment of the potential of new models for predicting the photodynamic 
therapy outcome in vitro. 
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Chapter 2  




Photobiology: the science of light and life 
 
 
Photobiology deals with the interaction of light with living organisms, 
from cellular to in vivo live specimens. This chapter describes the 
general techniques and methods involving both light and life: specific 
methods and techniques used for the determination of photophysical 
properties in the light-induced reaction processes; and the basics of 
liposome preparation and characterization, cell culture protocols and 
animal handling. Specific details will be described in the experimental 
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2.1. STEADY-STATE OPTICAL TECHNIQUES 
2.1.1. Absorbance and transmittance 
Spectra were recorded in both a Varian Cary 4E spectrophotometer (Varian, Palo Alto, 
CA) and a Cary 6000i UV-Vis-NIR spectrophotometer (Agilent Technologies, Santa 
Clara, CA). For diffuse transmittance measurements of cell suspensions, the 
spectrophotometer was equipped with 110 mm-diameter integrating sphere and a high 
performance photomultiplier tube. Integrating spheres have the ability to collect most 
reflected or transmitted radiation from turbid, translucent or opaque samples, removing 
any directional preferences and presenting an integrated signal to the detector.  
 
2.1.2. Emission 
Fluorescence emission and excitation spectra were recorded in both a Spex 
Fluoromax-2 spectrofluorometer and a Fluoromax-4 spectrofluorometer (Horiba Jobin-
Ybon, Edison, NJ). The absorbance of the sample was ensured to be less than 0.05 in 
the overlap region between absorption and emission to avoid inner filter effects in the 
measurement of fluorescence.  
Method 
Fluorescence quantum yield (F) 
The fluorescence quantum yields were determined from the comparison of the area 
under the corrected emission curves of optically-matched solutions of the sample to 
that of a suitable reference (i.e. with a similar emission spectrum as the sample). The 
quantum yields (F) were determined by means of Eq. 2.1: 
 
𝛷 (sample) = ·· · 𝛷 (ref)  (2.1) 
 
where Fi is the fluorescence intensity integrated over the entire emission spectrum 
corrected by the absorption factor (1-10-A) and ni is the refractive index of the solvent 
used in each case.  
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2.2. TIME-RESOLVED OPTICAL TECHNIQUES 
The time-resolved techniques used in this work involve the observation, through 
absorption or emission, of excited states or other reaction intermediates generated 
upon pulsed-laser irradiation of a sample. The formation of a large concentration of 
transient species upon absorption of light produced a change in the intensity of an 
analyzing beam (in the case of absorption spectroscopy) or in the intensity that 
emerges from the sample (in the case of emission spectroscopy), which the system is 
able to monitor with time resolution. 
 
2.2.1. Time-correlated single photon counting (TCSPC) 
Time-correlated Single Photon Counting is the most commonly used technique for 
singlet state lifetime determination. It is based on the detection of single photons of a 
periodical light signal, the measurement of the detection times of the individual photons 
and the reconstruction of the waveform form the individual time measurements. 
TCSPC technique makes use of the fact for low-level, high-repetition-rate pulses, the 
produced light intensity is so low that the probability of detecting one photon in one 
signal period is much less than one. Therefore, it is not necessary to provide for the 
possibility of detecting several photons in one signal period. It is sufficient to record the 
photons, measure their time in the signal period, and build up a histogram of the 
photon times.  
The principle is shown in Fig. 2.1: 
 
Figure 2.1. Principle of classic time-correlated single photon counting. From [1] 
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In most cases, the lifetime of the sample to be measured is on the same time scale as 
the response function of the system. In these cases, the actual decay may be obtained 
by deconvolution of the measured signal using an instrumental response function (IRF) 
generated from a light scattering sample. 
TCSPC experiments were carried out using a PicoQuant Fluotime 200 (PicoQuant 
GmbH, Berlin, Germany) fluorescence lifetime system. Excitation was achieved by 
means of picosecond diode lasers or LEDs (PicoQuant, 10 MHz repetition rate) and the 
counting frequency was always below 1%. Desired wavelength was selected by a 
monochromator (model 9055, Science Tech Inc., London, Canada) and an UV/Vis 
photomultiplier (model H5783-P01, Hamamatsu Photonics, Japan), sensitive from 175 
to 900 nm, was used to detect the fluorescence. Singlet state lifetimes were 
determined using the PicoQuant FluoFit 4.0 data analysis software. 
Method 
Singlet lifetime (s) 
A solution of the sample in the proper solvent was prepared ensuring that the 
absorbance of the sample was less than 0.05 in the overlap region between absorption 
and emission to avoid inner filter effects. The deconvolution of the TCSPC 
fluorescence signal with the IRF signal – reference sample (Ludox® in water) that 
directs a small fraction of the excitation light into the detection path - yields the singlet 
lifetime. 
 
2.2.2. Time-resolved NIR phosphorescence detection (TRPD) 
This technique is commonly used for directly and specifically monitoring the formation 
and decay of single oxygen (1O2, O2(a1g)), the measurement of its lifetime (∆) and its 
quantum yield of formation (∆) [2] . It is based on the detection of the weak 1O2 
phosphorescence, centered at 1275 nm. 
The 1O2 phosphorescence was detected using a customized PicoQuant Fluotime 200 
system (Fig. 2.2). A diode-pumped pulsed Nd:YAG laser (FTSS355-Q, Crystal Laser, 
Berlin, Germany) working at 10 kHz repetition rate and emitting either at 355 nm (5 
mW, 0.5 J per pulse) or 532 nm (10 mW, 1 J per pulse) was used for excitation. A 
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1064 nm rugate notch filter (Edmund Optics, York, UK) was placed at the exit port of 








region. The luminescence exiting from the cuvette or solid sample was passed through 
a cold mirror and a series of long-pass filters of increasing cut-off wavelengths (CVI 
Melles Griot, Alburquerque, NM) to remove any scattered laser irradiation, and filtered 
by suitable interference filters to isolate 1O2 emission. A TE-cooled Hamamatsu NIR 
photomultiplier (model H9170-45, Hamamatsu Photonics, Japan), sensitive from 950 to 
1400, was used to detect the conditioned NIR luminescence. The detector was 
operated in photon counting mode and its output sent to a PicoQuant Nanoharp 250 
multichannel scaler. The count histograms were built up until a sufficient signal-to-noise 
ratio was attained. Data was processed using the PicoQuant FluoFit 4.0 software. 
 
Methods 
Photosensitizer’s  triplet  lifetime  (T) and 1O2 lifetime (∆) 
Singlet oxygen lifetime was obtained by fitting Eq. 2.2 to the signal detected at 1275 
nm, 
𝑆(𝑡) = 𝑆(0) · · (𝑒 / − 𝑒 / )  (2.2) 
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where S(0) is the zero-time amplitude of the signal and T and ∆ are the actual 
lifetimes of the photosensitizer triplet state and singlet oxygen, respectively. 
Photosensitizer’s   lifetime  was   determined,   if   possible, by fitting Eq. 2.3 to the signal 
obtained at a wavelength where the triplet state of the photosensitizer emits, 
[ 𝑃𝑆   ] = 𝐾 · 𝑒 /   (2.3) 
 
where K1 reflects the concentration of triplet excited states of the photosensitizer and T 
is the actual lifetime of the photosensitizer triplet state. 
 
Quantum yield of 1O2 formation (∆) 
The quantum yield of singlet oxygen photosensitization is defined as the number of 
photosensitized 1O2 molecules per absorbed photon. The pre-exponential factor S(0), 
which is proportional to ∆, was determined by fitting Eq. 2.2 to the time-resolved 
phosphorescence intensity at 1275 nm. The quantum yields of 1O2 production were 
determined from the comparison of S(0) to that produced by an optically matched 
reference in the same solvent and at the same excitation wavelength and intensity (Eq. 
2.4) [2] . 
Φ (sample) = ( )( ) · Φ (ref)  (2.4) 
 
Quenching of 1O2 lifetime 
Stern-Volmer analysis was used to calculate reaction rate constants (kQ) form time-
resolved data, by means of Eq. 2.5: 
 
1 𝜏 = 1 𝜏 + 𝑘 [Q]  (2.5) 
 
where  and 0 are the lifetimes of the reacting species in the presence and absence of 
a quencher Q, respectively. 
 
2.2.3. UV-Vis nanosecond laser flash photolysis 
Transient absorption experiments in the UV-Vis region were carried out using a home-
built nanosecond laser flash photolysis system. In this instrument, the 2nd harmonic 
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(532 nm) or the 3rd harmonic (355 nm) of a Q-switched Nd:YAG laser (Surelite I-10, 
Continuum) was directed with right-angle geometry to irradiate the sample (10 Hz, 5 ns 
pulsewidth, 1-10 mJ per pulse). Changes in the sample absorbance were detected 
using a Hamamatsu R928 photomultiplier to monitor the intensity variation of an 
analyzing beam produced by a 75 W short-arc Xe lamp (PTI, Birmingham, NJ) and 
spectral discrimination was obtained using a dual-grating monochromator (mod. 101, 
PTI). The signal was fed to a Lecroy Wavesurfer 454 oscilloscope for digitizing and 
averaging (typically 10 shots) and finally transferred by a GPIB interface (National 
Instruments) to a PC computer for data storage and analysis. A Si photodiode (Laser-
Optotronic BPX 65) capturing a reflection of the laser beam was used to trigger the 
oscilloscope. The energy of the laser pulse was varied by neutral density filters and 
measured with a pyroelectric energymeter (RJP 735, Laser Precision Corp.). The 
system was controlled by software developed in our laboratory. 





Figure 2.3. Experimental set-up for nanosecond UV-Vis laser flash photolysis. 
 
  
Photobiology: the science of light and life 
 
27 
2.3. LIPOSOME PREPARATION AND CHARACTERIZATION 
2.3.1. Liposome preparation 
Liposomes used in chapters 4-6 were prepared by microemulsification or extrusion 
following standard procedures [3,4] . 
Method of microemulsification 
Lipid mixtures containing the photosensitizer were evaporated to dryness from a 
chloroform solution and kept in a vacuum desiccator for 12 h over P2O5 in order to 
remove the last traces of the solvent. Multilamellar vesicles (MLVs) were prepared by 
hydration of the dried lipid films by vortexing for 30 min (alternating 30 s periods of 
heating and 30 s of vortexing) at a concentration of 20 mg lipid/mL of 50 mM imidazole-
HCl buffer (pH 7.4) or 10 mM PBS buffer (pH 7.4) at a temperature above the phase 
transition temperature (Tm). The MLVs dispersion was frozen and thawed (five times), 
sonicated (bath sonicator, 15 min, T>Tm) and microemulsified (EmulsiFlex B3 device, 
Avestin, Ottawa, Canada). Microemulsification was carried out by pumping the fluid 
fifteen times through the interaction chamber (T>Tm, 200 kPa). Control liposomes were 
prepared in the same way but without the photosensitizer. The liposomes were stored 
in the dark at 4 ºC. Subsequent liposome handling procedures were all performed in 
the dark. 
Long-circulating liposomes with a polymer coating and folate-targeted liposomes 
incorporate the conjugated lipid (PEG3000-DSPE and folate-PEG2000-DSPE respectively) 
with the initial mixture of lipids.  
 
Method of extrusion  
MLVs were prepared as describe above using imidazole-HCl buffer (pH 7.4) for 
hydration.  In order to reduce and control particle size, MLV suspension was repeatedly 
extruded through different pore-sized polycarbonate membranes (Osmonics Inc., 
Livermore, CA) using an extrusion device from Lipex Biomembranes Inc. (Vancouver, 
Canada) at temperatures above the transition temperature (Tm) of the lipids and high 
pressure. Liposomes were then incubated for 30 min at T>Tm for annealing.  
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2.3.2. Liposome lyophilization 
To enhance stability during storage, liposomes were lyophilized using 5% trehalose as 
cryoprotectant agent.  
Method 
2 mL of liposomal suspension were placed in 4 mL glass vials and frozen at -80 ºC 
(liquid nitrogen) during 3-5 hours. Vials were subsequently dried during 24 h at -55 ºC 
and 0.04 mbar (Freeze Dryer Alpha 1-2/LD, Martin Christ GmbH, Germany). 
Lyophilized liposomes were rehydrated immediately before the experiments by adding 
2 mL of sterile water. The resulted suspension was prewarmed at 60 ºC during 15 min 
and vortexed for 30 min (alternating 30 s periods of heating/vortexing).  
 
2.3.3. Liposome characterization 
Determination of encapsulated photosensitizer 
The photosensitizer content in the liposomes was evaluated following standard 
procedures.  
Method  
Liposomes were disrupted by the addition of THF or DMSO to an aliquot of the 
liposomal suspension, free of non-entrapped photosensitizer and the absorbance was 
measured at max of the Soret band. The photosensitizer concentration was determined 
by comparison with standard curves obtained in the same conditions.  
 
Determination of lipid content 
Lipid content was quantified by a colorimetric assay with ammonium ferrothiocyanate 
according to the method of Stewart [5] .  
Method 
This colorimetric method is based on the formation of a complex between phospholipid 
and ammonium ferrothiocyanate that is soluble in chloroform. An aliquot of 10 L of 
liposomes is disrupted with 2 mL of chloroform and mixed with 2 mL of 0.1 M 
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ammonium thiocyanate (NH4SCN). After shaking with vortex for 1 min, the sample is 
centrifuged for 5 min at 4000 rpm. The reddish lower layer (chloroform) is removed with 
a Pasteur pipette and the absorbance is read in Specord 205 (Analytik Jena AG, Jena, 
Germany) at 470 nm. The phospholipid concentration is determined by comparison to 
the appropriate calibration curve obtained with known amounts of phospholipid.  
 
Determination of size and polydispersity 
The average size and polydispersity of unilamellar vesicles and the zeta potential were 
determined by photon correlation spectroscopy (PCS). A Zetasizer Nano-ZS (Malvern 
Instruments, UK) and a 4 mW He-Ne laser (Spectra Physics), at an excitation 
wavelength of 633 nm, were used. Before measuring, samples were appropriately 
diluted to avoid multiple scattering.  
 
Stability of formulations 
To control the stability of the formulations, the photosensitizer and lipid content in 
liposomes as well as the average size and polydispersity of the vesicles were also 
determined after storage up to 7 days. The stability of liposomes was also tested in 
presence of 10% FBS following the procedure described in [6] . 
Method 
Liposomal suspensions containing photosensitizer were incubated in buffer with 10% 
FBS at 37ºC with continuous stirring for different periods of time up to 48 h. After each 
incubation period, 200 L of the mixtures were withdrawn and centrifuged at 4000 rpm 
to eliminate any non-encapsulated photosensitizer, appeared as a result of the 
disruption of the liposomes due to its interaction with serum components. Then, 1.5 mL 
of THF or DMSO were added to 50 L of each supernatant to disrupt the liposomes, 
liberating the photosensitizer still encapsulated in the liposomes and precipitating the 
serum components. These samples were centrifuged at 4000 rpm to obtain a clear 
supernatant and the absorption spectra were recorded.   
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2.4. CELL CULTURES 
2.4.1. Cell lines 
Cell lines used in chapters 3 and 5 were Human HeLa cervical adenocarcinoma cell 
line (ATCC CCL-2) and human lung adenocarcinoma A549 cells (ATCC CCL-185). 
DBA/2 mastocytoma cell line, P815 (ATCC, TIB-64) [7]  and the BALB/c colon 
adenocarcinoma cell line CT26.CL25 (ATCC, CRL-2639) that expressed a tumor 
antigen, -galactosidase [8]  were used in chapter 6. Primary normal human dermal 
fibroblasts (hNDF) used in chapter 7 were kindly provided by Hospital de Oviedo. 
 
Culture conditions 
All cell lines are adherent cells and grow up to form cellular monolayers toward 
confluence after seeding. These cells were cultured at 37 ºC in a humidified sterile 
atmosphere of 95% air and 5% CO2, using Dulbecco´s Modified Eagle´s Medium 
(DMEM) or Roswell Park Memorial Institute (RPMI) supplemented with fetal bovine 
serum (10% v/v), glucose (4.5 g/L), L-glutamine (292 mg/L), streptomycin sulfate (10 
mg/L) and potassium penicillin (10000 U/L). CT26.CL25 cells were cultured in constant 
presence of 500 g/mL G418 antibiotic in order to maintain constant expression of the 
-galactosidase. 
  
Cell lines were maintained frozen in DMEM with 10% DMSO. 1.8 mL CryoTubesTM 
(Nunc, Nalge Nunc International, IL) were filled with the cell suspension and placed in a 
cell Cryo 1 ºC Freezing Container (Nalgene, Nalge Nunc International, IL) to be slowly 
frozen up to -80 ºC at a cooling rate of -1 ºC/min for successful cell cryopreservation. 
Frozen cells were rapidly transferred to a liquid nitrogen container (-196 ºC) and stored. 
 
  
Photobiology: the science of light and life 
 
31 
2.4.2. Dark toxicity 
The  photosensitizers’  effect  on  cell  viability   in  the  absence  of   light  was  determined  by  
the MTT colorimetric assay [9] . This assay detects living but not dead cells and it is 
based on the reduction of a tetrazolium salt to form a formazan dye. The electrons 
required by this process are given by the mitochondria of viable cells.  
Method 
Cells were seeded in 24 or 96-well plates and cultured until 80-85% confluence. They 
were then incubated in the dark with the photosensitizer for 18 h. After washing with 
sterile  Dulbecco’s  phosphate-buffered saline (PBS), DMEM containing 0.05 mg/mL 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added and 
incubated for 3 h at 37 ºC. The medium was replaced by DMSO and the absorbance at 
550 nm was read on a Bio-Rad Benchmark Plus microplate reader (Bio-Rad, Hercules, 
CA). Experiments were performed in triplicate. 
 
2.4.3. Cell uptake 
The cellular uptake of the studied photosensitizers was determined by fluorescence 
spectroscopy.  
Method 
Cells were seeded in 6-well plates and grown toward 80-85% confluence. Cells were 
incubated in the dark with the appropriate photosensitizer concentration, for different 
times ranging from 30 min to 30 h. In free folate competition studies in chapter 5, 1 mM 
folic acid was added to the incubation medium. Afterwards, the medium was discarded 
and the cells were washed three times with PBS, scrapped and resuspended in 1 mL 
of 2% sodium dodecyl sulphate (SDS) in Milli-Q water. The resulting suspension was 
centrifuged at 10,000 rpm for 10 min (Sigma 2-16P centrifuge, angle rotor 24x1.5/2.2 
mL). The extent of PS uptake was assessed by comparison between the fluorescence 
of this supernatant to that of standard solutions under the same conditions. The 
fluorescence intensity values obtained for each sample were normalized to the number 
of cells determined by the bicinchoninic acid (BCA) protein assay [10] . MicroBCA 
protein assay kit was purchased from Pierce Protein Research Products (Rockford, IL) 
and used according to the product information sheet. Each experiment was repeated 
twice.  
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2.4.4. Subcellular localization  
Confocal microscopy was used to examine the intracellular localization of 
photosensitizers taken up after delivery by the different systems. 
Method 
Cells were grown on 22 mm square coverslips placed into 35 mm culture dishes. They 
were incubated at 37 ºC for 18 h with DMEM containing the appropriate concentration 
of the photosensitizer. To confirm the intracellular localization of the photosensitizers, 
the endocytic compartments of the cells were labeled with the fluoroprobe LysoTracker 
Green DND-26, MitoTracker Green FM or ER-tracker green (Molecular Probes 
Invitrogen, Eugene, OR) in the culture medium at 37ºC for 30 min. After labeling, the 
coverslips were washed with PBS and 5-10 min later an Olympus FV1000, multi-
photon confocal microscope was used to image the cells. Quantification of overlap 
between organelle probes and the photosensitizer were carried out using image 
processing and analysis (IPA) software from the public domain (ImageJ 1.42; 
http://rsbweb.nih.gov/ij/index.html)  [11] . 
 
 
2.4.5. Light sources  
For the irradiation of cell cultures, it has been used two different light sources. In 
chapters 3-5, irradiation was carried out with Sorisa Photocare LED (Barcelona, Spain) 
source with wavelength range of 530 ± 20 nm (59 mW) or 625 ± 20 nm (145 mW). In 
chapter 6, irradiation was carried out with Lumacare lamp (Newport Beach, CA) fitted 
with a light guide and a 610-680 nm band-pass filter. The irradiance spectra are 
illustrated in Fig. 2.4. 
 
Figure 2.4. Irradiance spectra of the different light sources. 
400 500 600 700 800
Sorisa Photocare 530 nm
Lumacare 660 nm
Sorisa Photocare 625 nm 
Wavelength / nm
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2.4.6. Photodynamic treatments in vitro  
The photosensitizers’   effect   on   cell   viability   after   delivery  of   a   certain   light   dose  was  
determined by the MTT colorimetric assay described above. 
Method 
Cells were seeded in 96-well plates and cultured towards 80-85% confluence. They 
were then incubated in the dark at 37 ºC with DMEM containing the photosensitizer. 
After 18 or 24 h incubation, cells were washed three times with PBS and replenish with 
fresh media. Irradiation was carried out with a Sorisa Photocare LED or Lumacare light 
sources described above and the light intensity at the irradiation site was measured 
with a LaserStar Ophir power meter (Logan, UT). Cells were irradiated for different light 
doses and then incubated for 24 h before the MTT assay for cell viability. Experiments 
were performed in triplicate. 
 
 
2.4.7. Spectroscopic measurements of cell suspensions  
Spectroscopic measurements were recorded on the systems previously described. Cell 
suspension samples were prepared using the following method. 
Method 
Cells were incubated in the dark with the photosensitizer for 18 or 24 h. The medium 
was discarded and the cells were washed three times with PBS, scrapped or 
trypsinized and resuspended in 1.5 mL of PBS or D2O-based PBS (D-PBS). The 
samples contained about 8 millions of cells in 1.5 mL of PBS and were continuously 
stirred during the measurements. The measurements were then carried out within the 
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2.5.  ANIMAL MODELS 
2.5.1. Animal tumor models 
DBA/2 and BALB/c mice (6-8 weeks old) were purchased from Charles River 
Laboratories (Boston, MA). All experiments were carried out according to a protocol 
approved by the Subcommittee on Research Animal Care at (Institutional Animal Care 
and Use Committee) at Massachusetts General Hospital and were in accord with 
guidelines from the National Institutes of Health (NIH). Mice were inoculated with 
350,000 cells subcutaneously into the depilated left thigh. Two orthogonal dimensions 
(a and b) of the tumor were measured 3-4 times a week with a vernier caliper. Tumor 
volumes were calculated as 4/3 [(a+b)/4]3. PDT was performed when tumors reached 
a diameter of 5-7 mm (around 9 days after cell inoculation).  
 
2.5.2. PDT and tumor response 
The effects of photosensitizer formulation and targeting strategy on PDT effectiveness 
in vivo were evaluated as follows (Fig. 2.5).  
Method 
Tumor bearing mice were anaesthetized with an intraperitoneal injection of 87.5 mg/kg 
of ketamine and 12.5 mg/kg xylazine. Photosensitizer formulation (1 mg/kg) was 
administrated intravenously via the tail vein injection. 15 min or 24 h after injection of 
photosensitizer, 660-nm Lumacare light source was used to irradiate a homogeneous 
spot of 1.5-cm diameter that covered the tumor and a margin of normal tissue. A total 
fluence of 75 or 150 J/cm2 was delivered at a fluence rate of 100 mW/cm2. The mice 
were sacrificed when any of the tumor diameters exceeded 1.5 cm or when any signs 
of disseminated metastatic tumor appeared (e.g. >15% loss of body weight).    




Figure 2.5. Schematic depiction of the steps involved in performing PDT on a tumor model in mice. 
 
2.5.3. In vivo fluorescence imaging 
Photosensitizer accumulation and photobleaching in tumors were followed by 
fluorescence imaging. 
Method 
Tumor bearing mice were anaesthetized and subsequently placed in the light-tight 
chamber of the CRI Maestro (Caliper Life Sciences, Hopkinton, MA) in vivo 
fluorescence imaging system [12] . The instrument was set up as follows: images were 
captured every 10 nm throughout the wavelength range 650-800 nm using a 488-nm 
excitation filter, an LP 515-nm emission filter, and an exposure time of 100 ms. The 
focus and the stage height were set manually. Mice were imaged at different time 
points after photosensitizer tail vein injection. After the fluorescence image acquisition, 
the image cubes were unmixed (deconvolved) using a spectral library containing the 
autofluorescence of the mice skin and a dilute sample of photosensitizer. 
 
2.5.4. Vascular perfusion 
The effects of PDT on tumor vascular perfusion were studied using Hoechst 33342. 
The fluorescence of Hoechst 33342 is visible only in the functional vessels [13,14] .  
Method 
Vascular perfusion was assessed 1 h after PDT treatment by Hoechst 33342 injection 
(40 mg/kg in physiologic saline, i.v.) 1 min before sacrificing the animals by cervical 
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dislocation under deep anesthesia. After excision, tumors were snap-frozen in liquid 
nitrogen and stored at -80 ºC until sectioning. Sections of 5 m thickness were cut from 
the center of the tumor and examined under a fluorescence microscope (Axiovert, Carl 
Zeiss Microscopy, Thorwood, NY) with a 340-380-nm bandpass excitation filter and a 
430-nm long-pass filter.  
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Characterization of new porphycenes  
 
In this chapter, the photophysical properties of a group of new 
porphycene-based photosensitizers are determined. Among the 
photosensitizers tested, temocene, the porphycene analogue to 
temoporfin, shows the greatest potential for photodynamic therapy. 
Compared to temoporfin, temocene is endowed with 2.5-fold larger 
absorption coefficient in the red part of the spectrum while keeping its 
excellent photophysical and singlet oxygen photosensitization ability. 
While its photodynamic activity towards HeLa cells is lower than that of 
temoporfin, its higher photostability, lower dark toxicity and mitochondrial 
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3.1. INTRODUCTION 
During the last two decades a substantial effort has been put into the development and 
scrutiny of the second-generation photosensitizers (PSs)  [1-4] since no single PS has 
yet been found to meet all the demands for successful application in oncology.  
Amongst these second generation PSs, a series of derivatives of m-tetrahydroxyphenyl 
porphyrin (m-THPP) have been particularly promising [5,6]. The hydroxyl functions 
modulate the hydrophobic character of the macrocyclic core and therefore its solubility, 
and provide hydrogen bonding capability for specific interactions with receptor sites. 
One of the most active photosensitizers is m-tetrahydroxyphenyl chlorin (m-THPC, 
temoporfin) [7-9]. Although temoporfin is currently approved for photodynamic therapy 
(PDT) treatment of head and neck cancer under the trade name Foscan® [10,11], this 
PS is not without its own shortcomings due to its high potency and prolonged skin 
sensitivity [12,13].  
Amongst the porphyrin-based photodynamic therapy agents, porphycenes show better 
absorption properties than their structural isomers [14,15] owing to the lower molecular 
symmetry. The absorption on the red part of the spectrum, where the tissues are more 
transparent to light [16], the demonstrated cell photoinactivation [17-20] and the little 
photosensitivity associated [21] placed the porphycenes in an excellent position as 
promising candidates for PDT treatments. Since the synthesis of the first porphycene in 
1986 [22], a variety of substituted derivatives have been prepared [23] but the long and 
complex syntheses involved were a limiting factor until very recently.  
This chapter shows our contribution to the development of new porphycenes in order to 
find the optimal PS for PDT applications. In the light of the challenge set by Bonnett 
[24], who suggested the investigation of the corresponding m-tetra(hydroxyphenyl) 
porphycene derivative, we report on the photophysics, subcellular localization, and 
photodynamic activity of the porphycene analogue of temoporfin, which we term 
temocene. The photophysical properties of its precursor (m-tetra(isopropoxyphenyl) 
porphycene) and its palladium complex are also reported. Moreover, we studied the 
effect of carboxylate groups in the solubility and properties of the PS.  
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Figure 3.1. Chemical structures of pophycenes characterized in this chapter. 1. 2,7,12,17-(3-
carboxylatophenyl) porphycene, m-TCPPo; 2. 2,7,12,17-(3-isopropoxyphenyl) porphycene, iPrOTPPo; 3. 
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3.2. EXPERIMENTAL SECTION 
Liquid chromatography conditions. Liquid Chromatography (HPLC) was performed 
with a HP 1090 series liquid chromatograph equipped with a diode array detector. m-
THPPo was analyzed on a 30 mm x 4 mm, 3 mm particle, Lichrocart Purospher STAR 
RP-18E column. Detection was achieved at 375 nm. All chromatography runs were 
performed at room temperature with a mobile phase flow rate of 1.0 mL min-1. Isocratic 
elution was performed with 77:23 ACN/H2O. 
 
Photobleaching studies. Optically-matched solutions of m-THPC or m-THPPo in 
acetone were irradiated with a Q-switched Nd-YAG laser (Surelite I-10, Continuum) 
tuned to 532 nm. At intervals the cuvette was removed and the spectrum in the range 
of 450-800 was recorded in order to follow the course of photobleaching. 
 
Light dose and concentration dependence phototoxicity. HeLa cells were seeded 
in 24-well plates and cultured towards 80-85% confluence. They were then incubated 
in the dark at 37 ºC with serum-free DMEM containing 1-10 M m-THPPo in DMSO. 
After 18 h incubation, cells were washed three times with PBS and replenish with fresh 
DMEM. Irradiation was carried out with Sorisa Photocare LED source with wavelength 
range of 620-645nm. The light intensity at the irradiation site was 24 mW/cm2, 
measured with a LaserStar Ophir power meter. Cells were irradiated for different light 
doses and then incubated for 24 h before the MTT assay for cell viability. Experiments 
were performed in quadruplicate.  
 
Effect of ROS quenchers in temocene-induced phototoxicity. HeLa cells were 
seeded in 24-well plates and cultured towards 80-85% confluence. They were then 
incubated in the dark at 37 ºC with serum-free DMEM containing 1 M m-THPPo in 
DMSO. After 18 h incubation, cells were washed three times with PBS and incubated 
for 10 min with fresh DMEM containing D-mannitol (0.4 or 40 mM) as hydroxyl radical 
quencher or sodium azide (0.5 or 5 mM) as singlet oxygen scavenger. 5 J/cm2 light 
dose was delivered and cells were then incubated for 24 h before the MTT assay for 
cell viability. Experiments were performed in quadruplicate. 
. 
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3.3. RESULTS AND DISCUSSION 
Physical and photophysical properties. The photophysical properties of the 
tetraphenylporphycenes studied are discussed in detail in the following sections. A 
summary is given in Table 3.1.  
 
Table 3.1. Summary of photophysical properties of the porphycenes studied 
 
 
max, maximum of the lowest-energy absorption band; e, absorption coefficient at max; F, 
maximum of the emission bands; F, fluorescence quantum yield; S, singlet state lifetime; T, 
triplet excited state lifetime; kqO2, rate constant for triplet quenching by ground-sate oxygen; 
∆, singlet oxygen quantum yield.  
n.d. not determined 
n.a. not applied 
 
m-tetra(carboxylatophenyl) porphycene (m-TCPPo): a water-soluble porphycene 
One of the major drawbacks of the second-generation PSs is their poor solubility in 
aqueous environment. An attempt to solve this problem is to endow the hydrophobic 
core with carboxylate groups. As observed in Fig. 3.2, m-TCPPo shows the typical 
porphycene absorption spectrum in MeOH, with three bands in the red range of the 
spectrum.  The spectrum in water loses much of the structure, indicating not 
m-TCPPo iPrOTPPo  m-THPPo PdTPPo
(MeOH/H2O) (Benzene) (THF) (THF)
 max / nm 649/627 659 656 630
  / M-1 cm-1 n.d. 57 000 69 100 78 000
 F / nm 662, 717/ 655, 720 670, 735 666, 729 n.a.
 F  0.079/0.002 0.1 0.084 n.a.
 S / ns (Air) n.d. 3.8 2.3 n.a.
 T / s (Ar) n.d. n.d. 260 10
kq
O2 / M-1 s-1 n.d. n.d. 2.1 ·∙ 109 n.d.
    0.07/- 0.19 0.1 0.62
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surprisingly that aggregation is occurring in aqueous media despite the four negative 
charges.  
 
Figure 3.2. (A,C) Absorption and (B,D) fluorescence spectrum of m-(tetracarboxylatophenyl) porphycene 
in (A,B) MeOH and (C,D) water. Insets: Excitation spectra of the fluorescence at 730 nm. 
 
However, both in water and in MeOH, the fluorescence spectra match the typical 
fluorescence spectrum of porphycenes, with a main band and a weaker shoulder at 
lower energies that mirror the S1  S0 absorption transition [15]. Interestingly, the 
excitation spectrum matches in all cases the absorption spectrum of the monomer, 
indicating that the aggregates are not emissive. The fluorescence quantum yield, F, 
was 0.079 ± 0.005 in MeOH, and 0.002 ± 0.005 was found in water.  
The singlet oxygen production quantum yield, ∆, was determined by means of its 
phosphorescence at 1275 nm. ∆ value of 0.07 ± 0.02 was determined in MeOH upon 
excitation of 532 nm. In aqueous media aggregation strongly prevents its 
photosensitizing ability. These results fully agree with the water-soluble tricationic 
porphycene recently studied in our group [25].  
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m-tetra(hydroxyphenyl) porphycene (m-THPPo) and m-tetra(isopropoxyphenyl) 
porphycene (m-iPrOPPo): the temocene and its precursor 
As observed in Fig. 3.3, m-THPPo showed the typical absorption spectrum of free-base 
porphycenes, with three intense bands in the red part of the spectrum showing a 
maximum absorption coefficient of ca. 70,000 M-1 cm-1 at 656 nm, 2.5-fold higher than 
that of temoporfin [6]. The fluorescence emission spectrum also matched the typical 
fluorescence spectrum of porphycenes, with a main band at 666 nm and a weaker 
shoulder at lower energies that mirror the S1S0 absorption transition [15]. m-
iPrOTPPo showed no significant differences in the absorption and emission properties 
(see Table 3.1). The fluorescence quantum yield was F = 0.084 ± 0.005 for m-THPPo 
and F = 0.1 ± 0.02 for m-iPrOTPPo, suggesting that both temocene and its precursor 








The excited singlet state decayed with lifetime 2.3 ± 0.1 ns for m-THPPo (Fig. 3.4) and 
3.8 ± 0.1 ns for m-iPrOTPPo. The newborn triplet state lived 260 s in argon-saturated 
solutions, long enough to provide for rich photochemistry (Fig. 3.5).  
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Figure 3.5. Triplet-minus-singlet absorption spectrum of m-THPPo in argon-saturated acetone. Inset: 
Transient decay at 490nm. 
 
Indeed, temocene was able to photosensitize the production of singlet oxygen (1O2) in 
aerated solutions. The quantum yield, ∆ = 0.10 ± 0.01, was high enough to expect 
substantial phototoxicity to cells. The quantum yield for its precursor m-iPrOTPPo was 
∆ = 0.19 ± 0.02. 
As shown in Fig. 3.6 the rate constant for triplet decay (1/T) increased linearly with the 
concentration of oxygen, yielding a quenching rate constant of 2.1 x 109 M-1 s-1 for 
temocene. 
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Figure 3.6. Stern-Volmer plot of 1/T  at different oxygen concentrations in THF. 
 
The kinetics of temocene and temoporfin photobleaching under the same irradiation 
conditions were comparatively shown in Fig. 3.7. Temocene was substantially more 
photostable than temoporfin. 
   
Figure 3.7. Photobleaching of temoporfin and temocene solutions in aerated acetone upon irradiation with 
532-nm laser pulses. Absorbance values were recorded at 656 and 650 nm, respectively. 
 
 
Palladium(II)-2,7,12,17-(3-hydroxyphenyl) porphycene (PdTHPPo) 
The absorption spectrum of PdTPPo is shown in Fig. 3.8. Compared to m-THPPo the 
three Q-bands were reduced to two as a result of the increase of symmetry. The 
lowest-energy Q-band suffered a hypsochromic shift reflecting electron donation from 
the metal into the pophycene, thus raising their energy. The presence of metal also led 
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to an increase in the absorption coefficient of the lowest energy Q-band. These 




Figure 3.8. Absorption spectra of PdTHPPo (solid line) and m-THPPo (dotted line) in THF. 
 
PdTHPPo did not show fluorescence, an analogous situation to that found for PdTPPo 
[26]. This reflects an enhancement of the intersystem crossing probability owing to the 
heavy-atom effects.  
The triplet PdTHPPo decayed with monoexponential kinetics with a lifetime of 10 s in 
acetone (Fig. 3.9), much shorter to that of m-THPPo. In spite of this fact, it was still 
long enough to be deactivated by oxygen, yielding a ∆ = 0.62 ± 0.05. 
 
Figure 3.9. Transient absorption of triplet PdTHPPo in argon-saturated acetone (exc=355 nm, em=490 
nm).  
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In the light of the promising results obtained for m-THPPo, the synthetic availability and 
its analogy to temoporfin, one of the PS clinically approved, we decided to test its in 
vitro photodynamic activity. 
 
Photosensitization experiments. Studies on the dark- and phototoxicity of temocene 
and temoporfin are summarized in Fig. 3.10. HeLa cells were incubated in the dark with 




Figure 3.10. Viability of HeLa cells measured by the MTT assay after 18 h incubation with different 
concentrations of m-THPPo or m-THPC in DMSO. (A) Dark toxicity. (B) Photodynamic induced cytotoxicity 
after 3.5 J·cm-2. Mean ± SD from at least four independent experiments are shown.    
 
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay  [27] was 
performed 24 h after treatment to establish the m-THPPo and m-THPC dark toxicity. 
Our studies show that temocene is substantially less toxic in the dark than temoporfin, 
which is advantageous for its therapeutic applications. The photodynamic damage on 
HeLa cells was assessed after delivery of different light doses from a LED source at 
625 nm. Complete cell inactivation could be achieved at light doses of just 3.5 J·cm-2 
using m-THPPo concentrations higher than 5 M. At higher light doses the same result 
could be obtained at concomitantly lower temocene concentrations.  
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Effect of ROS quenchers on cell phototoxicity. To determine which ROS is 
predominantly involved in cell death, the phototoxicity of temocene to HeLa cells was 
evaluated in the presence of ROS inhibitors, namely D-mannitol (0.4 and 40 mM) as an 
HO•  quencher  and  sodium azide (0.5 and 5 mM) as a 1O2 scavenger. Fig. 3.11. shows 
dose-dependent inhibitory effects of D-mannitol and sodium azide. The phototoxicity of 
temocene was partially quenched by sodium azide but not by D-mannitol suggesting 
that singlet oxygen is the mainly responsible for cell cytotoxicity.  
 
 
Figure 3.11. Cell survival (%) of HeLa cells treated with 1 M temocene in the absence of ROS quenchers 
and in the presence of sodium azide (NaN3, 1O2 quencher) or D-mannitol (HO• radical scavenger) after 5 
J/cm2 light dose. Mean ± SD from at least four independent experiments are shown. *** p < 0.001 vs no 
ROS quenchers. 
 
Subcellular localization by fluorescence microscopy. Fluorescence micrographs of 
HeLa cells after 18 h incubation with temocene are shown in Fig. 3.12. Cells incubated 
with 0.5 M m-THPPo showed a fluorescence pattern similar to that of control cells. 
With 1 M and especially 10 M m-THPPo, a red fluorescence could be distinguished, 
which colocalized with the blue mitochondrial autofluorescence and with the green 
emission from MitoTracker®Green (Fig. 3.12A and merged image 3.12C), indicating 
that mitochondria are the main sites of temocene accumulation. This is fortunate as this 
organelle is one of the most attractive PDT targets for triggering apoptosis  [28-30]. In 
addition, a diffuse red fluorescence could be detected in the cytoplasm. No 
relocalization of the PS was observed when cells were exposed to prolonged 
irradiation. 
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Figure 3.12. Fluorescence microscopy images of living HeLa cells incubated with MitoTracker®Green for 
30 min, followed by 18 h 10 M DMSO-loaded m-THPPo. (A) Cells observed under blue excitation. (B) 
Cells observed under UV excitation. (C) Merged image. Scale bar: 20 m. 
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3.4. CONCLUSIONS 
In summary, we have reported the photophysical properties of a collection of new 
porphycene-base PSs. The introduction of carboxylate groups in the periphery of the 
PS core enhances its aqueous solubility although aggregation is not avoided in this 
environment. However, the monomeric porphycene is a far worse PS than the parent 
TPPo. The introduction of metals in the porphycene macrocycle induces a 
hyperchromic effect in the lowest energy Q-band and high singlet oxygen formation 
quantum yield. The results of these studies provide clues for improving the design of 
novel PS based on the porphycene macrocycle. 
We also have characterized temocene, a porphycene analogue to temoporfin. Its 
excellent photophysical properties, mitochondrial localization, and, above all, its 
photodynamic efficiency, make temocene a promising candidate for antitumoral 
photodynamic therapy. Compared to temoporfin, temocene shows lower activity but 
also lower dark toxicity and superior photostability. Taken together, temocene is 
endowed with potential value for photodynamic treatments and is worth of further 
studies. Development of a liposome-based formulation of temocene for its improved 
cell delivery and in vivo photodynamic activity is described in the following chapters.  
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3.6. ANNEX 
Synthesis. Temocene was synthesized using a procedure based in the four-step 
synthesis of porphycenes recently developed by our group  [31] (Fig. A1) and it was 
performed by Dr. Sánchez-García. Thus the isopropoxy ethers of porphycene were 
deprotected to the corresponding hydroxy derivative by addition of anhydrous 
aluminum trichloride to a dichloromethane solution of isopropoxy compound. In order to 
compare temocene and its chlorin analogue, temoporfin was synthesized using a 
published procedure  [32].  
 
 
Figure A1. Synthetic pathway used for the synthesis of porphyecenes. 
 
 
Purity of m-THPPo. Liquid chromatography was used to assess the purity of m-
THPPo. As shown in Fig. A2, a majority peak can be observed at 5.4 min, with a 
relative integral intensity higher than 97%. The minority peaks observed at 10.0 and 
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Figure A2. Liquid chromatography of m-THPPo detected at 375 nm. 
 
UV-Vis spectra were recorded every 1 s and found to be identical throughout the peak 
(Fig. A3). 
 
Figure A3. Absorption spectrum of m-THPPo peak at 4.3 min obtained by liquid chromatography and 
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Developing the ideal formulation 
 
 
The use of drug delivery systems for photosensitizing drugs has 
received strong interest within the field of photodynamic therapy (PDT). 
Liposomes, with their high loading capacity and their flexibility to 
accommodate different photosensitizers, came into focus as valuable 
carriers for PDT. This chapter describes the development of two 
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4.1. INTRODUCTION 
As we have seen in previous chapters, new photosensitizers (PSs) are continuously 
being developed to enhance their safety and therapeutic efficiency. Most of these PSs 
are hydrophobic and easily aggregate in aqueous solutions, but the monomeric state is 
required to maintain their photophysical and biological properties for efficient PDT 
outcome [1]. Therefore, various pharmaceutical carriers have been developed for the 
administration of photosensitizers, including oil-based emulsions, polymeric 
nanoparticles or liposomes.  
Liposomes are uni- or multilamellar phospholipid nano-vesicles that allow the 
incorporation of a great variety of drugs in their matrix because of their particular 
nature. The lipid bilayer can incorporate highly hydrophobic PSs and prevent their 
aggregation. On the other hand, the aqueous core is capable of encapsulating water-
soluble molecules. Liposomes not only protect PSs from the aqueous environment and 
metabolic processes, but also provide a large drug payload per particle and improve 
pharmacokinetics, thus enhancing safety and efficacy of PDT. Moreover, liposomes 
can prolong the action of drug by slow release of the PS and can modify the 
internalization and localization once the PS-loaded liposomes reach the targeted cells 
[2]. 
Their components (basically natural or synthetic phospholipids) are materials also 
existing in the body, and therefore provide high biocompatibility and biodegradability [3-
5].  The choice of phospholipids and preparation methods are crucial for defining the 
physical and chemical properties of liposomes, such as size, surface charge density 
and membrane packing constrains [6]. The lipids normally used are the egg or soybean 
natural extracts, phosphatidylcholine, phosphatidylethalonamine, phosphatidylserine, 
phosphatidic acid or phosphatidylglycerol with saturated or unsaturated chains. 
Cholesterol is often included to stabilize the bilayer [7]. 
Various preparation methods are available for formulate liposomes of different size and 
lamellarity. Ethanol injection is probably one of the easiest methods available. It 
involves the injection of a small volume of ethanolic solution of lipids into a large 
volume of water. The force of the injection ensures homogeneous mixing of lipids, as 
does the immediate dilution of the ethanol in the large excess of water. Resulting 
suspension is then dialyzed in order to remove any trace of remaining ethanol. This 
procedure generates mainly small unilamellar vesicles with diameters around 25-50 nm 
[8]. Membrane extrusion is a common method for the preparation of unilamellar 
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liposomes entrapping hydrophilic drugs. Lipid mixture containing the PS was 
evaporated to form a dry lipid film, which is hydrated with the desired buffer to form 
multilamellar vesicles. The suspension is prefiltered through filters with pores ~1 µm 
followed by several extrusions through filters with a pore size of 0.4 and 0.2 µm. The 
extrusion method yields the best vesicles with respect to the homogeneity of size 
distribution and to control the size of vesicles [6]. The method of emulsification also 
starts from the formation of a dry lipid film that contains the photosensitizer. Hydration 
is followed by size reduction passing through a high-pressure homogeneizer preheated 
above the transition temperature of the lipids for several cycles at high pressure (~200 
kPa). The advantages of this method are its simplicity for scaleup, large capacity and 
short preparation times [6]. Sonication method places the multilamellar vesicles 
suspension in a bath sonicator. Normally a 5-10 min sonication procedure (above the 
transition temperature of the lipids) is sufficient to prepare small vesicles with a 
diameter < 100 nm.  
Regardless of the preparation method, liposomes are generally classified in three main 
groups (Fig. 4.1). 
 
 
Figure 4.1. Schematic structures of the different types of liposomes. 
 
Conventional liposomes can be defined as liposomes that are typically composed of 
only phospholipids (neutral and/or negatively charged) and/or cholesterol. They can 
vary widely in their physicochemical properties such as size, lipid composition, surface 
charge and fluidity of the bilayer. Although manipulation of these properties can modify, 
to a certain extent, the in vivo behavior of conventional liposomes, conventional 
Developing the ideal formulation 
63 
liposomes are characterized by a relatively short blood circulation time [2]. Two 
different phenomena impair the circulation time of conventional liposomes: the lipid 
exchange between liposomes and lipoproteins that leads to an irreversible 
disintegration of the liposomes; and the easy opsonization by plasma proteins leading 
to the uptake by macrophages of the reticuloendothelial system (RES) [4]. In spite of 
this fact, conventional liposomes are widely used for in vitro conditions. The presence 
of glycolipids or protective polymers such as polyethylene glycol (PEG) grafted to the 
liposomal surface increase the circulation half-time to values of up to 12 h [9]. Long-
circulating liposomes are also referred as “sterically stabilized” or Stealth® liposomes. 
With prolonged circulation time, a greater concentration of liposomes can passively 
accumulate in the tumor by the enhanced permeability and retention (EPR) effect, 
which increases the amount of PSs available for internalization in tumor cells for 
improved PDT efficacy. But this passive targeting via the EPR effect may not be 
sufficient for increasing the amount of PSs internalized into targeted tumor cells. 
Therefore, active tumor targeting has been explored through liposome surface 
modification. Cancer cells can be differentiated from surrounding normal cells by 
various biomarkers, such as overexpressed receptors and enzymes on tumor cells 
specifically used for their rapid proliferation [10]. Targeting ligands, including 
antibodies, aptamers, peptides, or small molecules (e.g. folate), grafted to the liposome 
surface, have been demonstrated to actively target liposomes to diseased tissues 
[3,4,11]. An extended view of how folate-targeted liposomes could enhance PDT 
selectivity is described in chapter 5.  
We reported in this work the development and optimization of a liposomal formulation 
for two porphycene-based photosensitizers: Palladium(II)-tetraphenylporphycene 
(PdTPPo) and m-(tetrahydroxyphenyl)porphycene (m-THPPo). We have put every 
effort into obtain long-term stable formulations which incorporate the PS in a 
monomeric state.      
 
! !
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4.2. EXPERIMENTAL SECTION 
Materials. Palladium(II)-tetraphenylporphycene (PdTPPo) was synthesized as 
described previously [12,13]. The synthesis and photophysical characterization of m-
(tetrahydroxyphenyl) porphycene (temocene, m-THPPo) is described in detail in 
chapter 3. Dimyristoyl-, dipalmitoyl- and distearoylphosphatidylcholine (DMPC, DPPC, 
DSPC); 1-palmitoyl-2-oleoylphosphatidylcholine (POPC); dimyristoyl-, dipalmitoyl- and 
distearoylphosphatidylglycerol (sodium salts, DMPG, DPPG, DSPG); 1,2-
dioleoylphosphatidylserine (sodium salt, OOPS); 1,2-
distearoylphosphatidylethanolamine-N-[methoxy(polyethylene glycol)-3000] (m-
PEG3000-DSPE), egg extract phosphatidylcholine (egg-PC) and soy extract 
phosphatidylcholine (soy-PC) were purchased from Avanti Polar Lipids (Birmingham, 
AL). Thiobarbituric acid (≥ 98%), trichloroacetic acid (≥ 99%) and malondialdehyde 
tetrabutylammonium salt (≥ 96%) were purchased from Sigma-Aldrich Chemical Co. 
(St. Louis, MO). All other chemicals were commercially available reagents of at least 
analytical grade. Milli-Q water (Millipore Bedford, Massachusetts system, resistivity of 
18 MW cm) was used.   
 
Lipid peroxidation measured by TBARS. 500 µL liposome suspension (2 mg/mL) 
were mixed with 2 mL thiobarbituric reactive species (TBARS) kit (0.375% 
thiobarbituric acid, 15% trichloroacetic acid, 0.25 M HCl) and were boiled in water for 
15 min. The reaction was stopped with ice and centrifuge at 4000 rpm for 10 min. The 
extent of lipid peroxidation was assessed by comparison between the absorption of this 
supernatant at 532 nm to that of standard solutions of malondialdehyde (MDA) under 
the same conditions.  !  
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4.3. RESULTS AND DISCUSSION 
4.3.1. Palladium porphycene formulation: overcoming the problems 
 
Liposomes containing PdTPPo were prepared by microemulsification. Soy extract 
phosphatidylcholine (soy-PC) was chosen for these formulations. Its high unsaturation 
(up to 80% of the lipid components are unsaturated) makes easier the incorporation of 
molecules with high volume like PdTPPo. Different photosensitizer/lipid molar ratios 
have been tested ranging from 1:100 to 1:1000. Their characteristics are displayed in 
Fig. 4.2.  
 
!
Figure 4.2. Characteristics of PdTPPo/soy-PC formulations. A) Table of characteristics of the different 
formulations as measured by PS and lipid content. B) Aggregation state of PdTPPo as measured by the 
changes on absorption spectra of PdTPPo. Spectrum of PdTPPo in THF is given for comparison. 
 
 
The photosensitizer/lipid molar ratio had great influence on the loading capacity of the 
vesicles. With an increased number of molecules per liposome (lower molar ratio) the 
percentage of encapsulated PS decreased dramatically. In contrast, using a molar ratio 
of 1:600 or 1:1000 we were able to encapsulate ca. 100% of the molecules present at 
the initial stage of the liposomal formulation. Regarding the aggregation state, we could 
observe a decrease of the Q band in the absorption spectra of PdTPPo in all cases. 
However, the spectra did not lose much of the structure, indicating that aggregation 
occurred but in some extent. The molar ratio PdTPPo/soy-PC of 1:600 was chosen as 
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The peroxidation of the lipids in highly unsaturated formulations has been commonly 
reported [14]. Thus, the stability of formulations was followed by thiobarbituric acid 
reactive species (TBARS) assay to quantify the formation of end products of lipid 
peroxidation, specifically malondialdehyde (MDA) (Fig. 4.3).   
 
!
Figure 4.3. Lipid peroxidation of liposomal formulations as function of storage time measured by TBARS 
assay.  
 
As we can observe in the figure, both PdTPPo/soy-PC and control liposomal 
formulations were degraded by peroxidation, even when they were storage under 
nitrogen atmosphere. In order to enhance storage stability, we carried out two different 
strategies in parallel: change of lipid components and lyophilization of liposomes.   
 
 
Change of lipid components 
 
Several formulations were tested for the encapsulation of PdTPPo. A summary is given 
in Table 4.1. In general, the more fluidity of the bilayer, the better encapsulation of the 
PS in the bilayer. That resulted in better encapsulation yields, better stability after one 
week and more extent of PS in monomeric state (Fig. 4.4). This fact was also reflected 
in the size (zeta average) of the liposomes. The formulations with saturated lipids 
yielded bigger vesicles. These rigid bilayers have to enlarge their radius of curvature in 
order to accommodate the PdTPPo within. Among all the formulations tested, 
PdTPPo/POPC/OOPS in 1:450:150 molar ratio can be regarded as a good alternative 
liposomal composition as it yielded high PS encapsulation and preserved the 
monomeric state of PdTPPo.      
  














Developing the ideal formulation 
67 
Table 4.1. Physicochemical characteristics of the different formulations as measured by PS and lipid 








!Figure 4.4. Aggregation state of PdTPPo in selected formulations as measured by the changes on 
absorption spectra of PdTPPo. Spectrum of PdTPPo in THF is given for comparison.  Arrow indicates the 




Formulation Molar ratio L(%)a PS(%)b Zave/nmc ζpot/mV
d
PdTPPo/DPPC (1:600) 80 ± 2 60 ± 5(1) 250 ± 20 1.2 ± 1
PdTPPo/DMPC/DMPG (1:540:60) 73 ± 2 60 ± 5(1) 180 ± 10 -50 ± 5
PdTPPo/POPC/OOPS (1:540:60) 76 ± 5 72 ± 5(1) 200 ± 10 -32 ± 8
PdTPPo/POPC/OOPS (1:480:120) 75 ± 5 80 ± 5 177 ± 10 -41 ± 5
PdTPPo/POPC/OOPS (1:450:150) 87 ± 2 75 ± 5 150 ± 10 -47 ± 5
PdTPPo/Egg-PC (1:600) 75 ± 2(2) 87 ± 5 150 ± 15 -26 ± 5
a L: Lipid content
b PS: Photosensitizer content
c Z average mean
d Zeta potential
(1)  PS=30% after one week
(2)  Lipid oxidation after one week
Data mean ± SD of at least three different measures





























Lyophilization of the liposomal suspensions is a traditional strategy to ensure the 
stability of the formulations [15]. There are several parameters affecting the protective 
effect during liposome lyophilization. In order to choose the optimal formulation and 
technological parameters for lyophilization process we followed an experimental design 
based on Taguchi’s method L9(34). We defined 4 factors and 3 levels: 
• Cryoprotectant: sucrose, trehalose and mannitol.  
• % cryoprotectant: 2.5%, 5% and 10% 
• Agitation time after hydration: 10, 20 and 30 min 
• Storage time: 2, 4 and 6 weeks  
 
Sample: soy-PC liposomes 
 
Following the standard procedure for lyophilization and hydration, we measured the 
following parameters: size, zeta potential, lipid content and lipid peroxidation (TBARS). 
Size of the vesicles was highly influenced by the cryoprotectant used as shown in Fig. 
4.5A. The other parameters did not show differences independently of the factor used. 




Figure 4.5. A) Pareto analysis of the contribution of each factor to the size of liposomes. B) Lipid 
peroxidation of liposomal formulations after 2 weeks storage in the fridge or lyophilized. 
 
 
We considered the following condition as optimal for soy-PC liposome lyophilization: 
5% trehalose, 20 min agitation, storage stability > 6 weeks. 
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Having guaranteed the stability of the formulations, we assessed the dark cytotoxicity 
and photodynamic action of PdTPPo encapsulated in soy-PC liposomes (Fig. 4.6). 
Lyophilized formulations were rehydrated just before the experiments. HeLa cells were 
incubated for 18 h with different concentrations of PdTPPo encapsulated in soy-PC 
liposomes. Control liposomes without PS were also tested. Afterwards, cells were 
exposed to 3.5 J/cm2 red light using a LED source. Cell survival was assessed by MTT 
assay 24 h after treatment. 
 
 
Figure 4.6. Dark and photodynamic induced toxicity of soy-PC liposomes with or without PdTPPo. Mean ± 
SD from at least three different experiments are shown. 
 
 
The toxicity induced by the carrier itself was even higher than the PdTPPo containing 
liposomes. No effect was observed after delivering 3.5 J/cm2. The drug/lipid molar ratio 
of these formulations was increased up to 1:600 for an efficient encapsulation of 
PdTPPo, and therefore, the high concentration of lipids added to the incubation media 
caused an inherent cytotoxicity. After these results, the formulation was discarded. 
 
  
Chapter 4: Liposomes as vehicles for delivery of photosensitizing agents 
!
70 
4.3.2. Development of temocene liposomal formulation 
 
Temocene is the porphycene analogue to temoporfin (Foscan®). It has been 
developed a liposomal formulation for this potent PS (Foslip®) in order to avoid 
problems of drug precipitation after injection [16-18]. Based on these previous works 
and because temocene is a structural isomer of temoporfin, we first attempted the 
liposomal formulation using Biolitec’s formulation Foslip® (18 mg/mL DPPC, 2 mg/mL 
DPPG and 1.5 mg/mL m-THPC) as reference formulation [19]. Thus, we tested two 
preparations, m-THPPo/DSPC/DSPG (1:10:1.1) and m-THPPo/DPPC/DPPG 
(1:11:1.2), using extrusion or microemulsification methods. Results are summarized in 
Table 4.2. 
 
Table 4.2. Physicochemical characteristics of the different formulations as measured by PS and particle 
size. 
    
 
 
In this first iteration, extrusion was discarded for controlling the size of the vesicles after 
hydration. Temocene, because of its high hydrophobicity, was completely retained in 
the polycarbonate filters of the extruder. Furthermore, the formulation m-
THPPo/DSPC/DSPG was also discarded. Its high phase transition temperature (above 
45ºC [16]) made the suspension as a solid gel, not suitable for injectable formulations.    
 
 
In a second approach, lipid mixtures of different chain length were tested. Phospholipid 
chains of different length cause discontinuities in the lipid membrane where the 
photosensitizer can accommodate.  As we can see in Table 4.3, PS encapsulation 
yields have improved considerably but they were still too low. Moreover, the resulting 
liposomes were too large with high polydispersity. This indicated that the radius of 
curvature is very constrained and therefore the bilayer could not accommodate many 
PS molecules resulting in a low encapsulation yield and large vesicles.  
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Increasing the drug/lipid relation to 1:25 we obtained better encapsulation yields but 




Table 4.4. Physicochemical characteristics of the different formulations (PS/lipid molar ratio 1:25) as 




The best results were obtained with DPPC/DMPG formulation, although the temocene 
content is still low.  The drug/lipid molar ratio was then increased to 1:75 and 1:100 
using this formulation (Table 4.5). Both liposomal suspensions showed good 
encapsulation yields with a vesicle size close to 120 nm.  We chose m-
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Table 4.5. Physicochemical characteristics of m-THPPo/DPPC/DMPG formulations as measured by PS 




The local concentration of the solubilized porphycene in the liposome bilayer can be 
estimated by means of the total number of lipid molecules per liposome (Nlip). Nlip can 








!     (4.1) 
 
 
where DH is the hydrodynamic diameter, h is the thickness of the bilayer (3.7 nm for 
DPPC vesicles [21]) and a is the cross-sectional area of the polar head of lipids (0.71 
nm2 for phosphatidylcholine [22]). Considering our liposomes are composed only by 
DPPC lipids, the number of lipid molecules per liposome is Nlip = 119 817 molecules. 
Since the molar ratio PS/lipid is 1:75, the number of photosensitizer molecules in a 
liposome is NPS = 1597 molecules (2.6 x 10-21 mol). The volume of a liposome is 
calculated as follows (Eq. 4.2): 
 
! = 4/3!(!!! )! − 4/3!(
!!!!
! )!    (4.2) 
 
The volume of a liposome is therefore 1.6 x 10-19 L. Thus, the local concentration of 
temocene in a liposome of 120 nm diameter is 0.016 M. This high local concentration 
of temocene inside the liposome can influence the photophysical properties of the PS.  
 
As we observed in Fig. 4.7 temocene in liposomes presented a structured absorption 
spectra without presence of any additional bands typical of aggregates. This result 
evidenced that although the high local concentration, the PS is still in a monomeric 
state.  
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Figure 4.7. Absorption spectra of temocene in DPPC/DMPG liposomes and in THF. 
 
 
The absorption spectrum measured of liposomes included two contributions: 
absorption of encapsulated temocene and scattering of the vesicles, the latter more 
evident at lower wavelengths. The determination of fluorescence quantum yield (ΦF) 
was therefore influenced by this fact. It was calculated from the comparison of the area 
under the emission curve of optically-matched solutions of the sample to that of a 





Figure 4.8. Absorption (A) and emission (B) spectra of cresyl violet in MeOH (violet) and temocene 
encapsulated in liposomes (blue). 
 
 
Considering that there would be less molecules of photosensitizer than that we were 
adjusting because of the scattering contribution, we expressed the fluorescence 
quantum yield as ΦF ≥ 0.02 ± 0.003.  
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The same holds true for the singlet oxygen quantum yield (Φ∆) (Fig. 4.9) and therefore 
it was expressed as Φ∆ ≥ 0.082 ± 0.02. 
 
 
Figure 4.9. Absorption (A) and singlet oxygen phosphorescence (B) spectra of TMPyP in water (red) and 
temocene encapsulated in liposomes (blue). 
 
 
The singlet lifetime of temocene encapsulated in liposomes decayed with a lifetime of 
τS = 1.6 ± 0.2 ns (Fig. 4.10), substantially lower than that of temocene in THF (τS = 2.3 
± 0.2 ns). 
 
Figure 4.10. Fluorescence decay of temocene encapsulated in liposomes (λexc = 375 nm, λem = 660 nm) 
 
 
Although the PS was apparently in a monomeric state regarding its absorption 
spectrum, the fluorescence and singlet oxygen quantum yields and the singlet lifetime 
of temocene inside the liposomes indicated that liposomes affected in some extent the 
photophysical characteristics of the photosensitizer. This effect could be due to the 
high local concentration of the temocene inside the liposomal bilayer (16 mM) and 
therefore the formation of dimers, trimmers and high order aggregates can occur. A 
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similar effect was observed for liposomal encapsulated chlorins [23]. The high local 
concentration of the PS induced remarkable changes in the photophysical properties. 
However, after being incorporated to human skin fibroblasts, the PSs existed as 
monomers inside the cells showing the same photophysical properties as in organic 




An ideal formulation should be endowed with long-term stability and easy manipulation. 
Many methods are available for liposome stabilization such as freezing or spray-drying, 
though lyophilization is the main approach used to extent the self-life of liposomes [15]. 
Using the conditions optimized for soy-PC liposomes (5% trehalose as cryoprotectant 
and 20 min agitation during hydration), we studied the effect of lyophilization process 
on the physicochemical properties of the temocene liposomal formulation (Table 4.6).  
   
 




As expected, the size of liposomes was increased due to the fusion/aggregation of 
vesicles although it was maintained within the optimal size range for cellular 
internalization. Neither the PS content nor the aggregation state was influenced by 
lyophilization. This process ensured the stability of liposomal formulations during 
several months of storage.  




In this work, we have faced up to the development of different liposomal formulations 
for the delivery of two porphycene-based photosensitizers: PdTPPo and m-THPPo.  
The effect of palladium coordination was not only reflected in the photophysical 
properties of the porphycene, but also in its liposomal encapsulation. The insertion of 
the metal ion in the macrocycle cavity distorted the geometry of the macrocycle core 
and therefore its planarity [24]. This distortion hampered its packaging within the lipid 
bilayer, decreasing the number of PS molecules per liposome. We found 1:600 a 
drug/lipid molar ratio that allowed high PdTPPo encapsulation yields with minimal 
aggregation. We used highly unsaturated lipids with high fluidity (phosphatidylcholine 
soy extract) to facilitate the incorporation of the photosensitizer. However, these 
unsaturations led to the peroxidation of the lipids. To enhance the stability of the 
formulations we proposed two strategies: change the lipid components to lower 
unsaturated chains that avoid peroxidation (PdTPPo/POPC/OOPS, 1:450:150 molar 
ratio) or lyophilize the soy-PC liposomal formulation. We have optimized the 
parameters for an optimal lyophilization of the liposomal formulations. However, the 
reconstituted liposomal suspension was not suitable for cellular experiments since it 
was cytotoxic by itself.   
We also developed the liposomal formulation for temocene. We found that m-
THPPo/DPPC/DMPG (1:67.5:7.5 molar ratio) yielded a high encapsulation rate with 
liposome sizes of ca. 120 nm. The local concentration of temocene inside the 
liposomal bilayer was 16 mM. This high concentration could lead to the formation of 
aggregates affecting the photophysical properties of temocene in some extent. In spite 
of this fact, we assumed that DPPC/DMPG liposomes are a good drug delivery system 
for temocene photosensitizer that fulfills the requirements of an ideal carrier for PDT: 
avoid aggregation of the PS in aqueous environments providing a high drug payload. 
The influence of liposomes in internalization, subcellular localization and in vivo 
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